Experts and Doctors on papillary cystadenocarcinoma in United States
Locale: United States
Topic: papillary cystadenocarcinoma
Ahluwalia A, Hurteau J, Bigsby R, Nephew K. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol. 2001;82:299-304 pubmed
DeHaven K, Taylor D, Gercel Taylor C. Comparison of serum vascular endothelial growth levels between patients with and without ovarian malignancies. Int J Gynecol Cancer. 2002;12:715-9 pubmed
..Based on our data, due to the lack of significant difference in mean serum VEGF values between patients with and without ovarian malignancies, we feel that serum VEGF cannot be used as a possible screening tool for ovarian cancer. ..
Villella J, Marchetti D, Odunsi K, Rodabaugh K, Driscoll D, Lele S. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2004;95:539-45 pubmed
..Adjuvant combination platinum-based agent with gemcitabine is a very effective and well-tolerated treatment for recurrent fallopian tube or ovarian carcinoma; even in those who exhibit initial platinum resistance. ..
Fader A, von Gruenigen V, Gibbons H, Abushahin F, Starks D, Markman M, et al
. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol. 2008;109:33-8 pubmed publisher
..Age, performance status and other geriatric parameters should be considered when dosing chemotherapy in the elderly. ..
Fader A, Drake R, O Malley D, Gibbons H, Huh W, Havrilesky L, et al
. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer. 2009;115:2119-27 pubmed publisher
..Recurrence and survival outcomes are improved in well-staged patients treated with platinum/taxane-based chemotherapy. This multi-institutional study is the largest to support systemic therapy for early stage UPSC patients. ..
Leeborg N, Thompson M, Rossmiller S, Gross N, White C, Gatter K. Diagnostic pitfalls in syringocystadenocarcinoma papilliferum: case report and review of the literature. Arch Pathol Lab Med. 2010;134:1205-9 pubmed publisher
..We describe our findings and diagnostic pitfalls to help pathologists encountering this unusual apocrine neoplasm. ..
Tunuguntla R, Ripley D, Sang Q, Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer. Gynecol Oncol. 2003;89:453-9 pubmed
..MMP-26 and TIMP-4 are expressed in endometrium and endometrial carcinoma and their elevated expression and correlation with myometrial invasion suggests that MMP-26 and TIMP-4 may play a key role in endometrial tumor progression. ..
Creasman W, Kohler M, Odicino F, Maisonneuve P, Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004;95:593-6 pubmed
..The purpose of this study was to evaluate patients with uterine papillary serous carcinoma (UPSC), clear cell (CC), and grade 3 endometrioid (G3) surgically stage I endometrial cancer...
Konecny G, Agarwal R, Keeney G, Winterhoff B, Jones M, Mariani A, et al
. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol. 2008;109:263-9 pubmed publisher
..Our aim was to determine the expression pattern and prognostic relevance of claudin-3 and claudin-4 in a large cohort of endometrial cancer patients of diverse histological type and stage...